improve the results of cyclophosphamide or 5-fluorouracil treatment, but there were no statististically significant differences. In contrast, bleomycin treatment in combination with adjuvant anticoagulation suggested a possible drug synergy. No significant influence of anticoagulation on the response of the primary tumour to irradiation was found, though the MST of irradiated and anticoagulated animals was greater than in the solely irradiated controls. The present investigations suggest that coumarin derivatives have some direct tumour-inhibiting capacities, but exert their antimetastatic action via deceleration of the blood clotting mechanism.
FIBRIN formation around intravascular tumour cell emboli is considered to be of importance for the establishment of haematogenous metastases (Wood, 1971) . On the other hand, fibrin has been detected within and around solid tumours, and it was assumed that this would favour the invasive growth of malignant tissue (O'Meara and Jackson, 1958) . Under experimental conditions, the pharmacological alteration of the host's clotting mechanism suggested the pathogenic significance of blood coagulation in the growth and dissemination of tumours (Wood, 1974) . Various anticoagulants have been used to influence the spread of rodent tumours, yet many of the results reported are contradictory. The experimental systems most widely used were lung colony assays after i.v. injection of tumour cell suspensions. Since these systems are highly artificial and do not correlate with any known clinical condition, the interest has focused on spontaneously metastasising tumours. Since the first report of the effects of dicumarol on circulating Brown-Pearce carcinoma cells in rabbits by Strauss and Saphir (1949) , anticoagulation with coumarin derivatives has been a frequent approach to altering the blood coagulability of tumour-bearing animals (Hagmar, 1970) .
The present investigations deal with the effects of controlled long-term anticoagulation on primary and metastatic growth of the spontaneously metastasising Lewis lung carcinoma (3LL). Furthermore, some effects of anticoagulation in combination with conventional chemotherapy and radiotherapy were investigated.
MATERIAL AND METHODS
Animals.-C57BL/6 J-Han spf mice of both sexes were used throughout the experiments. The weight range was between 17 and 22 g. The animals were fed with commercial pellets (Altromin 8) and allowed to drink tap water ad libitum. (Wexler, 1965 
RESULTS

Anticoagukltion
The oral medication ofphenprocoumon, with daily adjustment of the dose, resulted in a stable state of anticoagulation throughout the entire study. Death from haemorrhage was infrequent, the loss of animals within a single experiment in the anticoagulated groups never exceeding 10%. During the experiments, all ani-mals were regularly weighed, and the weight gain in control and anticoagulated groups was always identical. An example of the weight development in control (n-30) and phenprocoumontreated (n 40) tumour-bearing animals is given in Table I . 19-5 0-3 18-6 1 0 22-2 0 3 significant effect was seen if the drug was administered from Days 1-10 of tumour growth (P < 0.05). However, there was still some tumour inhibition by shortterm treatment (Days 4-9 and Days 7-9, Fig. 2 ). Effect of anticoagulation on primary tumour growth This is shown in Fig. 1 by the growth curves of tumours in control (n = 12) and anticoagulated animals (n = 15). Phenprocoumon was given throughout the entire period of tumour growth. It is obvious that there was a significant inhibition of tumour growth on Day 12 (P < 0-01). In another experiment, the influence of limited anticoagulation on tumour growth was tested in 3 groups of 10 animals each. Anticoagulation was established by i.p. injections of phenprocoumon. The maximum and most Table II , short-term anticoagulation was ineffective in reducing lung metastases.
Only those animals receiving phenprocoumon from Days 0-20 had significantly fewer lung tumours, thus confirming the previous experiment (Fig. 3) . Shortterm therapy (Days 7-9) was given i.p., whereas treatment from Days 0-11, 0-20 and intermittent anticoagulation (Days 0-20) was oral.
Survival studies The MST of 12 control animals bearing the Lewis lung carcinoma was 29-4 days. Anticoagulation from Day 0 to 15 resulted in a MST of 31*1 days in 15 animals, T/C thus being 106%. This difference is not statistically significant. Fig. 4 demonstrates the distribution of the death rates in the two groups. It will be noted that, despite the similar MST, the onset of death of the anticoagulated animals was clearly delayed.
Anticoagulation and chemotherapy
In all experiments, phenprocoumon was given from Day 0 until the end of the study (Day 16 or 19) . The effect of cyclophosphamide treatment alone, and in combination with anticoagulation, on primary and metastatic tumour growth is shown in Fig. 5 Thornes, Edlow and Wood, 1968 (Brown, 1973;  Ryan, Ketcham and Wexler, 1968) . No data concerning the toxicity were given in these studies. In our experience, death from haemorrhage is a frequent event which is closely related to the degree of anticoagulation. Since, in the present investigations, anticoagulant therapy was daily monitored and individually adjusted in each experiment, toxic deaths were almost eliminated. The body weight development of anticoagulated and corresponding control animals was identical in each experiment, indicating that drug toxicity was minimal (Table I) . This is important in the light of the known sensitivity of the Lewis lung carcinoma to variations of the host's weight gain.
Continuous oral anticoagulation led to a depression of the growth curves of the primary tumour, and it seemed that this effect was not directly related to the metastasis-inhibiting capacity of this therapy. Even short-term i.p. application of phenprocoumon led to some inhibition of primary tumour growth (Fig. 2) , whereas only continuous oral long-term anticoagulation was effective in preventing tumour metastasis (Table II) . Intermittent phenprocoumon therapy throughout the period of tumour growth had no antimetastatic effect, indicating that the reduction of pulmonary metastasis could be mediated by the deceleration of the clotting mechanism (Brown, 1973) , thus requiring a stable state of anticoagulation. An effect of anticoagulation on the early release of viable tumour cells, as a consequence of effects on the primary tumour, is unlikely, since phenprocoumon therapy throughout the first 10 days after tumour transplantation did not prevent lung (Thornes, 1975 (Fig. 7) . The combined treatment of long-term anticoagulation and bleomycin suggested drug synergy, although the antimetastatic effects of this combined treatment were not pronounced. The combination of anticoagulation with local tumour irradiation had no obvious synergistic effects on primary tumour growth when compared to irradiation alone. The analysis of the death rates of animals with this combined treatment schedule, however, indicates that the prevention of lung metastases by oral anticoagulation was effective in approximately one third of the tumour-bearing mice, leading to a prolongation of the life span of these animals.
From the present experiments, it can be concluded that anticoagulation with coumarin derivatives is effective in reducing the growth and spread of a malignant tumour. It seems rational to take advantage of this capacity and to combine oral anticoagulation with conventional chemotherapy or radiotherapy. The present animal data suggest that additive actions against the tumour could reduce the toxicity of cytotoxic drugs, and preliminary clinical data indicate that anticoagulants are comparatively safe, even in advanced cancer (Elias, Shukla and Mink, 1975 
